InsiderPulseNo transactions found.
No financial data available for TAK.
Company may not file with SEC or CIK is unresolved.
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
IgA Nephropathy Market Forecast to 2036: Novel Therapies and Key Growth Drivers Fuel Expansion | DelveInsight
What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in
HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Pancreatic Neuroendocrine Tumors Market Research Report 2025-2035, Competitive Analysis of Key Players - Novartis, Pfizer, Exelixis, Merck, Ipsen Pharma, and Takeda Pharma
Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.
Immunology drug developer Odyssey seeks U.S. IPO again
Johnson & Johnson: Why I See Downside Ahead
My Top 4 Pharma Picks Under Rising Geopolitical Risk
Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade)